76 results on '"Grothey, Axel"'
Search Results
2. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation
3. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162–170
4. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
5. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
6. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
7. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
8. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years
9. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines
10. Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting
11. Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program
12. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
13. A new prognostic and predictive tool for shared decision making in stage III colon cancer
14. Evolving role of regorafenib for the treatment of advanced cancers
15. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
16. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
17. Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials
18. EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?
19. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
20. Molecular profile of BRCA-mutated biliary tract cancers
21. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
22. Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II
23. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
24. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine
25. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers
26. Regorafenib Dose-Optimization Study (ReDOS): A Phase 2 Randomized Study to Evaluate Dosing Strategies for Regorafenib in Patients with Refractory Metastatic Colorectal Cancer - An ACCRU Network Study
27. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database
28. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
29. Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience
30. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
31. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance)
32. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set
33. Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers
34. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer
35. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
36. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016
37. Adverse event development in clinical oncology trials – Authors' reply
38. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254
39. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
40. Biologics and immunotherapy in metastatic colorectal cancer
41. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
42. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
43. The role of regorafenib in metastatic colorectal cancer
44. When less is more: maintenance therapy in colorectal cancer
45. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
46. Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147
47. Efficacy of Chemotherapy After Treatment with Regorafenib in Metastatic Colorectal Cancer (MCRC)
48. Adjuvant Regorafenib in Stage IV Colorectal Cancer (CRC) After Curative Treatment of Liver Metastases: A Phase III Randomized, Placebo-Controlled Study (COAST)
49. Phase III Randomized, Placebo(Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1
50. Population Pharmacokinetics Analysis of Regorafenib and Its Active Metabolites From the Phase III Correct Study of Metastatic Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.